Overview

This trial is active, not recruiting.

Conditions influenza, hiv infections
Sponsor Uniformed Services University of the Health Sciences
Collaborator Infectious Diseases Clinical Research Program
Start date October 2009
End date December 2009
Trial size 132 participants
Trial identifier NCT00996970, IDCRP-053

Summary

The purpose of this research is to determine the effectiveness of the novel H1Nl influenza (inactivated/killed formulation) vaccine among both HIV-infected and HIV-uninfected persons. The administration of the H1Nl vaccination is not part of the study's procedures, but is being given as part of routine care.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Measure
To compare the immunogenicity via anti-hemagglutinin responses following H1N1 vaccination between HIV positive and negative persons.
time frame: interim = 2 months; 6 month f/u = 8 months

Secondary Outcomes

Measure
To compare the immunogenicity via HAI titer levels, microneutralization seroresponses and titer levels, and cellular responses following H1N1 vaccination between HIV positive and negative persons.
time frame: 1 year
Among those undergoing vaccination with the seasonal influenza vaccine during the current influenza season, to compare the presence of a positive seroresponse between HIV positive and negative persons
time frame: 1 year
To evaluate the effect of pre-existing anti-influenza immunity and recent history of seasonal influenza vaccination on seroresponses to the H1N1 influenza vaccine among both HIV positive and negative persons.
time frame: 1 year
To compare the durability of the H1N1 immunologic responses at 6 months post-vaccination between HIV-infected and uninfected persons.
time frame: 1 year
To evaluate the number of ILIs and documented influenza cases among HIV-infected and uninfected persons after initial vaccination, and to genetically characterize the influenza strains causing ILI events in our study cohort.
time frame: 1 year
To evaluate the impact of CD4 counts/percentages, HIV RNA levels, and HAART use on the immunologic responses to H1N1 vaccination in HIV positive subjects.
time frame: 1 year
To evaluate the impact of the H1N1 vaccine on CD4 counts/percentages and HIV RNA levels in HIV positive subjects.
time frame: 2 months
To evaluate potential adverse reactions of the H1N1 vaccine in HIV positive versus negative subjects.
time frame: 2 months

Eligibility Criteria

Male or female participants from 18 years up to 50 years old.

Inclusion Criteria: - 18-50 years of age - Receiving the novel H1N1 vaccine (killed formulation) as part of routine clinical care - A military beneficiary who expects to remain in the local area for the next 6 months Exclusion Criteria: - Healthcare worker who is involved in direct patient care - Acute febrile illnesses within 30 days prior to H1N1 vaccination (e.g., pneumonia, influenza, ILI) - Diabetes type 1 or type 2 - Systemic steroid or immunosuppressive medication use within 4 weeks of vaccination - Active diagnoses of a cancer (non-melanoma skin cancer allowed). - History of organ transplant - Chronic active hepatitis B or C - Active illicit drug use or alcohol abuse - Blood transfusion within the last year - Allergy to eggs - Previous significant adverse reaction (e.g., anaphylaxis) to the seasonal influenza vaccination - History of serious reactions to any prior vaccination (e.g., Guillain Barre Syndrome (GBS)). - Received another vaccination in the last 4 weeks (receipt of seasonal influenza vaccination is allowed) - Among females of childbearing potential, pregnant or within 6 weeks of being postpartum - History of ILI which was confirmed as an H1N1 infection

Additional Information

Official title Immunogenicity of Novel H1N1 Vaccination Among HIV-Infected Compared to HIV-Uninfected Persons
Description The investigators study is being conducted to evaluate and compare the seroresponses of the novel H1N1 vaccination among HIV positive and negative persons receiving the novel H1N1 vaccination as part of routine clinical care, with secondary objectives examining the impact of prior seasonal vaccinations on subsequent seroresponse to the novel H1N1 vaccination, determining potential reactions (local or systemic) to this new vaccine among patients, and assessing for potential immunologic/virologic changes (in CD4/HIV RNA levels) after H1N1 vaccination among HIV patients. Finally, the investigators will collect data on influenza-like illnesses (ILI) and H1N1 events during the study follow-up period and influenza isolates causing ILI events will be genetically characterized.
Trial information was received from ClinicalTrials.gov and was last updated in May 2015.
Information provided to ClinicalTrials.gov by Uniformed Services University of the Health Sciences.